XBiotech: Q2 Earnings Snapshot
XBiotech | 10-Q: Q2 2024 Earnings Report
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?
XBiotech Shares Are Trading Higher After the Company Shared Results From the 1-BETTER Study for Advanced Pancreatic Cancer.
XBiotech Says The Primary Endpoint For The Phase 2 Study Was To Assess The Safety And Tolerability Of Natrunix When Used With The ON+5FU+LV Combination, There Were Fewer Adverse Events Of Any Kind During The 24-Week Treatment Period For The Natrunix...
XBiotech Results From Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
XBiotech | 10-Q: Q1 2024 Earnings Report
XBiotech Inc.'s (NASDAQ:XBIT) Market Cap up US$57m Last Week, Benefiting Both Retail Investors Who Own 45% as Well as Insiders
XBiotech Inc.'s (NASDAQ:XBIT) Top Owners Are Retail Investors With 44% Stake, While 44% Is Held by Insiders
12 Health Care Stocks Moving In Monday's Pre-Market Session
XBiotech to Begin Constructing New R&D Facility on Its 48-acre Campus
ARCT, EHTH and CRTO Are Among After Hour Movers
Companies Like XBiotech (NASDAQ:XBIT) Are In A Position To Invest In Growth
Press Release: Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis
Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
Individual Investors Account for 50% of XBiotech Inc.'s (NASDAQ:XBIT) Ownership, While Insiders Account for 35%
12 Health Care Stocks Moving In Tuesday's After-Market Session
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
XBiotech Announces First Patient Begins Novel Natrunix Therapy In Phase II Rheumatoid Arthritis Clinical Trial